Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Jun 28, 2023 8:31pm

157 Views

Post# 35519618

Somethings smells here

Yesterday's new release of FDA approval for AKI phase 2 trial should have caught the attention of any interested investors. IMO yesterdays news should have got us back up to $5 with high volume. We had a mild bump up Monday and Tuesday (news release) to the tune of 15%. Today CIBC and Scotiabank knocked us on our a.. today closing down 5.25%. Something fishy here.

Just the mention of FDA would spark buying interest.

The other intresting point is there are multiple similar staged companies who have market caps of $1B to $2B and we are stuck at $125M. We know we have the science but why the major difference?? Something is not adding up here? Where are the buyers?

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec